|
Aug 9
|
Analysts Have Lowered Expectations For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Its Latest Results
|
|
Aug 6
|
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 6
|
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
|
|
Aug 6
|
EyePoint Pharmaceuticals: Q2 Earnings Snapshot
|
|
Aug 6
|
EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments
|
|
Jul 30
|
Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates
|
|
Jul 30
|
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025
|
|
Jul 30
|
Enrolment concludes in EyePoint’s Phase III programme of Duravyu for wet AMD
|
|
Jul 29
|
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
|
|
Jun 16
|
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
|
May 11
|
New Forecasts: Here's What Analysts Think The Future Holds For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
|
|
May 10
|
Earnings Beat: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
|
|
May 7
|
EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say
|
|
May 7
|
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 7
|
EyePoint Pharmaceuticals: Q1 Earnings Snapshot
|
|
May 7
|
EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments
|
|
Feb 26
|
EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025
|
|
Feb 25
|
EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference
|
|
Feb 11
|
Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?
|
|
Sep 4
|
EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
|